HR Execs on the Move

Neurotrope Inc

www.neurotropebioscience.com

 
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

New Bedford Medical Associates

New Bedford Medical Associates is a Fairhaven, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harbour Health Systems

Harbour Health Systems is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Cardiovascular Systems Corporation

Terumo Cardiovascular Systems' product line in perfusion circuits is not only one of the most comprehensive in the industry, but also offers an increasing array of products focused on helping surgical teams improve outcomes associated with

Hexagon Labs

Hexagon Labs is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genalyte

Since 2007, Genalyte has been guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes. We launched our first instrument in 2012 in the pharmaceutical industry and academia for a range of healthcare applications including autoimmune disease monitoring, screening of cancer biomarkers, testing for infectious agents and detecting anti-drug antibodies. By reducing tests to a microscopic size in a highly multiplex environment on the surface of silicon chips we are able to generate more information from a smaller sample in less time than conventional techniques.